ALZECA BIOSCIENCES, INC.

Medtech · Private

ADx-MR, a targeted liposomal contrast agent for magnetic resonance imaging of amyloid-beta plaques in Alzheimer's disease

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$1.6M
Federal grants
$1.6M
2 awards · 2017–2018
Rank in peer group#14 of 30
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

20172018FEDERAL ↑EQUITY ↓Cumulative $1.6M$943K$683K
20172018FEDERAL ↑EQUITY ↓Cumulative $1.6M$943K$683K

Latest events

  • Federal grantHealth and Human S · Phase II · Novel MRI Contrast Agent for Detection of Beta Amyloid$683K
  • Federal grantHealth and Human S · Phase II · Novel MRI Contrast Agent for Detection of Beta Amyloid$943K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 30 peers

Line = median

Medtech · Molecule

  • Federal grants#14 · top 47%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 1
  • PendingSurrogate Marker For Very Early Stage Tau Pathology Is Detectable By Magnetic Resonance ImagingUSPTOApplication 63287036

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .